Two Sigma Investments LP Purchases Shares of 1,844,423 Novo Nordisk A/S (NYSE:NVO)

Two Sigma Investments LP purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,844,423 shares of the company’s stock, valued at approximately $158,657,000.

Several other institutional investors also recently modified their holdings of the business. TrinityPoint Wealth LLC grew its position in shares of Novo Nordisk A/S by 9.6% in the 4th quarter. TrinityPoint Wealth LLC now owns 17,918 shares of the company’s stock valued at $1,541,000 after buying an additional 1,565 shares during the last quarter. Strive Asset Management LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $228,000. Toronto Dominion Bank increased its position in Novo Nordisk A/S by 494.1% during the 4th quarter. Toronto Dominion Bank now owns 88,295 shares of the company’s stock valued at $7,595,000 after purchasing an additional 73,432 shares during the period. Silvercrest Asset Management Group LLC lifted its position in shares of Novo Nordisk A/S by 3.1% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 127,998 shares of the company’s stock worth $11,010,000 after purchasing an additional 3,881 shares during the period. Finally, Sphera Funds Management LTD. boosted its stake in shares of Novo Nordisk A/S by 25.6% in the 4th quarter. Sphera Funds Management LTD. now owns 98,080 shares of the company’s stock valued at $8,437,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.7%

NVO opened at $64.35 on Monday. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm has a market capitalization of $288.75 billion, a PE ratio of 19.56, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company’s 50-day moving average is $67.31 and its 200 day moving average is $84.19.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion during the quarter. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on NVO shares. Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.